Temozolomide is an antineoplastic imidazotetrazinone that demonstrated clinical activity in the treatment of high-grade glioma, melanoma and mycosis fungoides during phase I clinical evaluation (Newlands et al., 1992) . Promising activity has also been observed in both recurrent and newly diagnosed high-grade astrocytomas in a preliminary phase II study (O'Reilly et al., 1993) . These responses were obtained when a total dose of 750-1000 mg m-2 temozolomide was fractionated into five equal doses and administered on consecutive days (p.o., repeated at 4 weekly intervals). Clinical activity of this compound is highly schedule dependent: no activity is observed if the equivalent total dose is administered as a single bolus.
The anti-tumour activity of temozolomide is attributed to methylation of the accessible nucleophilic centres in DNA, following chemical decomposition to 5-(3-methyl-triazeno) imidazole-4-carboxamide (MTIC) at mildly alkaline pH, and subsequent formation of a reactive methyldiazonium species (Denny et al., 1994) . Adduct formation at the 06 position of guanine in DNA is often found to be the major determinant of methylating agent cytotoxicity (Domoradzki et al., 1984; Margison and O'Connor, 1990) . It is assumed that 06-methylguanine is cytotoxic by virtue of the cell's attempts to process the methylated base during replication (Karran and Bignami, 1992) , a hypothesis supported by the demonstration that 06-methylguanine can hinder DNA replication in vitro (Ceccotti et al., 1993) . During replication on a template containing 06-methylguanine a non-semiconservative DNA synthesis occurs , which correlates with activation of the long patch mismatch repair pathway (Holmes et al., 1990 ). This post-replicative repair mechanism functions to maintain genomic fidelity and involves a specific protein that acts as a binding factor for the recognition of Correspondence: SR Wedge Received 9 August 1995; revised 27 September 1995; accepted 4 October 1995 GT mismatches (Jiricny et al., 1988; Griffin and Karran, 1993) . It is suggested that when this repair process is targeted to the strand directly opposite 06-methylguanine it is unable to find a complementary base and thus results in long-lived nicks in the DNA . These interruptions in the daughter strands inhibit replication in the subsequent S-phase (Plant and Roberts, 1971; Ceccotti et al., 1993) and account for methylating cytotoxicity being only apparent after at least two rounds of cell division (Catapano et al., 1987) . Since the anti-tumour activity of temozolomide is thought to depend upon the formation of 06-methylguanine, its clinical utility may be limited by the cytoprotective DNA repair protein, 06-alkylguanine -DNA alkyltransferase (AGT), which removes 06-alkylguanine adducts in a stoichiometric, autoinactivating reaction (Pegg, 1983; Tano et al., 1990 ). Resistance to temozolomide or MTIC readily induced in vitro is attributed to this DNA repair process (Hayward and Parsons, 1984; Catapano et al., 1987) .
Depletion of AGT, by pretreatment with the modified free base 06-BG (a substrate analogue) has been widely examined as a therapeutic strategy to circumvent AGT-mediated resistance to the chloroethylnitrosourea BCNU (Friedman et al., 1992; Mitchell et al., 1992; Felker et al., 1993; Gerson et al., 1993) . BCNU has proven clinically useful in the management of brain tumours and lymphomas (Young et al., 1971; Edwards et al., 1980) but has limited therapeutic efficacy because of intrinsic or acquired tumour resistance (Walker and Hurwitz, 1970; Carter and Wasserman, 1976 ). This compound rapidly decomposes at physiological pH to yield an alkylating chloroethyldiazonium ion and a carbamoylating isocyanate (Montgomery et al., 1967; Weinkam and Lin, 1979 (Tong et al., 1982) . It is this ability to cross-link DNA that correlates with chloroethylnitrosourea cytotoxicity (Lown et al., 1978; Bodell et al., 1985; Jiang et al., 1989) . AGT can prevent the formation of DNA cross-links not only by removal of the initial 06-chloroethylguanine adduct but also by reacting with the o6, N'-ethanoguanine intermediate (Gonzaga et al., 1992) . Because AGT can limit BCNU cytotoxicity, there is often a good correlation between cellular sensitivity to BCNU and AGT expression (Erickson et al., 1980; Brent et al., 1985; Mitchell et al., 1992) .
Methylating agents such as streptozotocin or temozolomide have been examined in combination with the chloroethylnitrosoureas as an alternative method of depleting AGT (D'Incalci et al., 1991; Panella et al., 1992; Mitchell and Dolan, 1993; Plowman et al., 1994) . However, a methylating agent itself may benefit from a protocol that involves depletion of AGT by an inhibitor such as 06-BG. This study examined the relationship between temozolomide cytotoxicity and AGT expression and the potentiation of cytotoxicity by 06-BG. These parameters were also examined with BCNU treatment and comparisons made not only with single doses but also with multiple dosing schedules to account for the schedule dependency of temozolomide cytotoxicity. 
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Results
Relationship between AGT activity and temozolomide or BCNU cytotoxicity A wide range of AGT activity was evident in the cell lines studied; from < 6 fmol mg ' protein for the glioblastoma cell lines to > 700 fmol mg'-protein in the breast carcinoma cell line MCF-7 (Table I ). There is controversy as to whether the relationship between AGT expressed as activity per cellular protein or cellular DNA is always linear, with standardisation to protein potentially being more variable because of differences in cell size (Gerson et al., 1986; Citron et al., 1991) . Since the correlation between AGT activity normalised to protein or DNA was linear in this study (Figure 1 ), it was acceptable to routinely express AGT activity in terms of cellular protein.
The relationship between the IC50 value obtained from a single treatment of BCNU (1 h) and AGT activity was relatively linear, such that cells with greater AGT were more resistant to BCNU (Figure 2 ). One distinct exception was the glioblastoma cell line U87MG, which had the lowest AGT expression, but which did not display greatest sensitivity to BCNU. The correlation between AGT activity and the IC50 value obtained from a single treatment of temozolomide (3 h) was also linear for a number of cell lines (Figure 2) (Table I ). This concentration also depleted AGT activity in U87MG and U373MG to a level which was undetectable, and was selected for use in sensitisation studies.
.: 100- (Table II) . LS174T was selected to determine whether the lack of potentiation observed with 06-BG and temozolomide on a single-dose schedule could be circumvented by repeat dosing, whereas Mawi was selected as being representative of a cell line in which depletion of AGT clearly did potentiate temozolomide cytotoxicity (Figure 4) . (Table II) . This phenomenon may be attributable to the development of resistance or to the variation in post-treatment incubation time, even though the shortest recovery period (72 h) would have accommodated at least four cell divisions of Mawi or LS174T. The mean intraexperimental potentiation of temozolomide cytotoxicity was found to increase linearly between days 1 and 5 (Figure 5a ), which would suggest that this assay did have the capacity to measure relative changes in cytotoxicity produced by treatment with 06-BG. In Mawi, potentiation of temozolomide cytotoxicity increased from 1.5+0.2-to 2.2+0.1-fold (days 1 to 5, mean+s.e.) with 100 ,uM 06-BG pretreatment, whereas BCNU cytotoxicity increased from 1.8+0.1-to 2.7+0.1-fold ( Figure 5 ). Continuous 1 ,uM 06-BG markedly increased the potentiation of temozolomide cytotoxicity (1.4 + 0.1-to 4.4 + 0.6- fold) and also further increased BCNU cytotoxicity, although by relatively less (2.6 + 0.2-to 3.8 + 0.3-fold). No appreciable potentiation of temozolomide cytotoxicity could be achieved in LS174T by repeat dosing with 06-BG treatment (Figure 6a ), even though potentiation of BCNU cytotoxicity was greatest in this cell line (Figure 6b ). Increasing potentiation of BCNU cytotoxicity was conferred by repeat dosing in both cell lines but was often limited to the first four doses. However, even when comparisons were restricted to between days 1 and 4, the net increase in potentiation of temozolomide cytotoxicity (mean + s.e.) afforded by repeat dosing with continuous 1 uM 06-BG was 2.5 + 0.3-fold in Mawi, which exceeded that observed with BCNU in either Mawi (0.6 + 0.1-fold) or LS174T (1.6 + 0.4-fold).
Discussion
This study was performed to contrast the potentiation of therapeutic methylation and chloroethylation by AGT depletion, and thereby determine whether the combination of temozolomide with 06-BG is worthy of consideration for clinical development. 
I
The relatively greater cytotoxicity of BCNU is a consequence of the DNA cross-link, a lesion which is highly toxic by virtue of its ability to obstruct RNA transcription and DNA replication (Erickson et al., 1980; Pieper et al., 1989) and which is responsible for the severe myelosuppression that often accompanies clinical usage of the chloro-ethylnitrosoureas. In contrast, methylating cytotoxicity is comparatively less: temozolomide is tolerated at an approximately 10-fold greater dose than its chloroethylating analogue mitozolomide (Newlands et al., 1985; Newlands et al., 1992) .
A linear correlation between AGT activity and chloroethylnitrosourea cytotoxicity has been described in a number of studies (Brent et al., 1985 Gerson et al., 1992 Sarker et al., 1993; ) and increasing evidence suggests that a similar relationship may also exist with chemotherapeutic methylators such as MNNG (Scudiero et al., 1984) , MTIC (Gibson et al., 1986) or temozolomide (Tisdale, 1987) . The results of this study support the existence of a correlation between temozolomide cytotoxicity and AGT activity, although exceptions were apparent. In particular, the colorectal cell line LS174T was as resistant to temozolomide as cell lines with 2.5-to 3.5-fold greater AGT activity. That resistance to temozolomide in this cell line was not dependent upon AGT activity was confirmed with both single and repeat dosing studies, in which depletion of AGT by 06-BG did not afford an increase in temozolomide cytotoxicity (Figures 4 and 6 ). This 'tolerance' to methylation may be attributable to loss of the mismatch repair pathway, which would normally generate DNA strand breaks and thereby induce cell death during the futile attempt to find a complementary base for o6-methylguanine (Griffin et al., 1994 Modrich, 1986): hMSH2 (Fishel et al., 1993) and GTBP/pl60 (Drummond et al., 1995; Palombo et al., 1995) . This structure interacts with another heterodimer consisting of hPMS2 and hMLH1 proteins (Li and Modrich, 1995) , which are homologues of the E. coli MutL repair protein (Grilley et al., 1989) . Thus, although extracts from LS174T have been found to exhibit normal G T mismatch binding in a bandshift assay (Branch et al., 1995) , a binding defect may exist within the interaction of the human MutS complex with a MutL homologue. The many additional instances in which methylating cytotoxicity and AGT activity appear unrelated (Baker et al., 1979; Scudiero et al., 1984; Goldmacher et al., 1986; GothGoldstein, 1987; Branch et al., 1993; Griffin and Karran, 1993; Kat et al., 1993) could also be possibly accounted for by a defect in any one of five mismatch repair genes (Papadopoulos et al., 1995) .
It should also be noted that the relationship between AGT activity and BCNU cytotoxicity is not always linear and that tumour models besides the glioblastoma U87MG in this study (Figure 3) have been known to demonstrate non-AGTmediated resistance to chloroethylating agents (Dolan et al., 1991; Silber et al., 1992) . Alternative mechanisms of resistance to BCNU include the activity of cellular glutathione S-transferases and glutathione levels, which may quench chloroethylated DNA monoadducts (Ali-Osman, 1989) or directly inactivate BCNU by denitrosation (Smith et al., 1989) . This latter reaction can also be catalysed by the cytochrome P450 mono-oxygenase system (Potter and Reed, 1983) . In addition, polyamine metabolism has been implicated in resistance to some alternative component of BCNU cytotoxicity, which is independent of cross-link formation (Seidenfeld et al., 1987) .
Potentiation of a single dose of chloroethylating or methylating agent by AGT depletion in vitro usually results in an enhancement of cytotoxicity of up to 5-fold, although potentiation of 10-to 12-fold has been documented (Marathi et al., 1993; Dolan et al., 1985a; Aida et al., 1987; Gerson et al., 1988) . It is suggested that this potentiation is dependent upon the level of AGT expression, with no potentiation being evident in cells with little AGT activity (Gerson et al., 1988; Dolan et al., 1991; Baer et al., 1993; Plowman et al., 1994) . The results obtained with the glioblastoma cell lines, U87MG and U373MG, would support this finding, since the AGT activity of these cell lines was less than 6 fmol mg-' protein and no potentiation of BCNU or temozolomide cytotoxicity could be achieved by pretreatment with 06-BG (Table I) . However, the enhancement of temozolomide or BCNU cytotoxicity in all other cell lines did not correlate with AGT activity (Figure 4) . This observation could not be accounted for by differences in cell doubling time and may imply that alternative resistance mechanisms are induced following AGT depletion. DNA alkylation may also produce perturbations of the cell cycle, which could conceivably affect the rate of AGT regeneration. This would have a more pronounced effect on the potentiation of temozolomide, not only because the repair protein has a greater affinity for 06-methyl adducts than for 06-chloroethyl adducts (Pegg et al., 1984; Brent, 1986 ) but also because post-replicative AGT regeneration will be of importance in regulating the cytotoxicity of methylation, which is dependent upon multiple rounds of cell division (Catapano et al., 1987) . That the potentiation of temozolomide cytotoxicity following a single 06-BG treatment was always less than that observed with BCNU ( Figure 4 ) may partly be attributable to the de novo synthesis of AGT following 06-BG treatment but is also likely to be a consequence of the greater toxicity of the DNA cross-link.
It is probable that the schedule-dependent activity of temozolomide is related to progressive AGT depletion, with each additional exposure to the drug increasing the retention of 06-methylguanine adducts . Thus it was not surprising to find that potentiation of temozolomide cytoxicity by an AGT inhibitor should increase with repeat dosing ( Figure Sa) . The maximal potentiation of temozolomide cytotoxicity observed in this study, following five consecutive doses, was 4-to 5-fold, which is in contrast to the 300-fold potentiation reported in a similar preliminary experiment (Baer et al., 1993) . However, the results of this latter investigation would seem extremely unlikely, given the magnitude of potentiation reported in the rest of the literature.
Extended 1 MM 06-BG treatment was clearly more efficacious than intermittent 100 JM 06-BG (1 h pretreatment every 24 h) in enhancing either BCNU or temozolomide cytotoxicity on five repeat doses (Figures 5 and 6b) . That optimal sensitisation to BCNU is dependent upon prolonged depletion of AGT would correlate with the findings of Marathi et al. (1994) . However, the regeneration of AGT following repeat dosing of 100 gmM 06-BG would be expected to be marginal, given that a single treatment inhibits AGT by > 90% for 24 h (Table I) . These results emphasise that relatively low levels of AGT can have profound effects on the cytotoxicity of methylating and chloroethylating agents.
Although the 06-BG treatments used in this study were not growth inhibitory, continual exposure to 06-BG alone for a period of 5 days did result in an IC50 value of 35-40 /iM in cell lines with an AGT activity as diverse as that of Mawi (>500 fmol mg-' protein) and U87MG (<3 fmol mgprotein) (data not shown). This non-specific toxicity should be kept in mind when considering the use of extended depletion studies, since the base analogues on single administration are generally considered to be non-toxic (Dolan et al., 1985b) . Hence, toxicological considerations may also be important in the selection of inhibitors, besides the capacity to deplete AGT and compound solubility.
One potential hazard associated with a potentiation of DNA methylation is the possibility that mutagenesis will also be enhanced, since the mispairing of 06-methylguanine in replication may result in G C to A T transitions (Yang et al., 1994; Mitra et al., 1989) . Correlations between mutagenesis and AGT activity have previously been demonstrated (Liu et al., 1994; Yarosh, 1985) , which suggests that the probability of carcinogenesis may also be increased if a methylating agent is combined with 06-BG. This may also apply to a combination of BCNU and 06-BG, since BCNU can form the carcinogenic lesion 6-(,B-hydroxyethyl)guanine (Tong et al., 1981) . Carcinogenicity will, however, depend upon a number of kinetic factors such as the level of cell proliferation and the possibility that AGT regeneration rates may vary in different tissues (Dolan et al., 1988) . Whether such parameters will severely limit the use of 06-BG as a therapeutic adjuvant is unclear, although the risk of inducing a secondary malignancy may be outweighed by the potential to significantly improve patient survival.
The fact that temozolomide does show clinical activity and is well tolerated (up to 6 weeks continuous administration in the current phase I study) suggests that a clinical combination of temozolomide with 06-BG may be preferred to a regimen involving BCNU and 06-BG, simply because the chloroethylnitrosoureas are more inherently toxic. Although 06-BG may exacerbate the relatively mild myelosuppression produced by temozolomide (Fairburn et al., 1995) this could, if necessary, be managed by autologous bone marrow infusion and the administration of haematopoietic growth factors. It is also possible that the gene for AGT (Tano et al., 1990) could be transfected into bone marrow cells before infusion and thereby confer greater haematological resistance to such therapy.
In conclusion, this study reinforces the importance of AGT as a determinant of methylating and chloroethylating agent cytotoxicity but also emphasises that alternative mechanisms of resistance may equally regulate sensitivity to these compounds. It also suggests that the combination of temozolomide with an inhibitor of AGT may have a clinical role in the treatment of tumours that exhibit AGT-mediated resistance, when administered via a repeat dosing schedule. 
